Last reviewed · How we verify
VTX002
At a glance
| Generic name | VTX002 |
|---|---|
| Also known as | OPL-002 |
| Sponsor | Oppilan Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS (PHASE1, PHASE2)
- VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VTX002 CI brief — competitive landscape report
- VTX002 updates RSS · CI watch RSS
- Oppilan Pharma Ltd portfolio CI